Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes

[1] Iacopetta D(2023)Targeting breast cancer: an overlook on current strategies Int J Mol Sci 396 1817-1828

[2] Ceramella J(2020)Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Lancet 306 128-141

[3] Baldino N(2005)The immunomodulatory protein B7–H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation Exp Cell Res 18 849-861

[4] Sinicropi MS(2003)B7–H4, a molecule of the B7 family, negatively regulates T cell immunity Immunity 276 40-51

[5] Catalano A(2017)Potential targeting of B7–H4 for the treatment of cancer Immunol Rev 29 1086-1101

[6] Cortes J(2023)Design and preclinical evaluation of a novel B7–H4-directed antibody-drug conjugate, AZD8205, alone and in combination with the PARP1-selective inhibitor AZD5305 Clin Cancer Res 336 175-203

[7] Cescon DW(2018)Indoleamine 2,3- dioxygenase and its therapeutic inhibition in cancer Int Rev Cell Mol Biol 20 1083-1097

[8] Rugo HS(2022)Indoleamine 2,3- dioxygenase (IDO) inhibitors and cancer immunotherapy Cancer Treat Rev 27 2212-2223

[9] Nowecki Z(2019)Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): A phase 3, randomised, double-blind study Lancet Oncol 23 370-378

[10] Im SA(2021)A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma Nat Med 12 394-400

[1] Iacopetta D(2023)Targeting breast cancer: an overlook on current strategies Int J Mol Sci 396 1817-1828

[2] Ceramella J(2020)Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Lancet 306 128-141

[3] Baldino N(2005)The immunomodulatory protein B7–H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation Exp Cell Res 18 849-861

[4] Sinicropi MS(2003)B7–H4, a molecule of the B7 family, negatively regulates T cell immunity Immunity 276 40-51

[5] Catalano A(2017)Potential targeting of B7–H4 for the treatment of cancer Immunol Rev 29 1086-1101

[6] Cortes J(2023)Design and preclinical evaluation of a novel B7–H4-directed antibody-drug conjugate, AZD8205, alone and in combination with the PARP1-selective inhibitor AZD5305 Clin Cancer Res 336 175-203

[7] Cescon DW(2018)Indoleamine 2,3- dioxygenase and its therapeutic inhibition in cancer Int Rev Cell Mol Biol 20 1083-1097

[8] Rugo HS(2022)Indoleamine 2,3- dioxygenase (IDO) inhibitors and cancer immunotherapy Cancer Treat Rev 27 2212-2223

[9] Nowecki Z(2019)Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): A phase 3, randomised, double-blind study Lancet Oncol 23 370-378

[10] Im SA(2021)A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma Nat Med 12 394-400